{"id":1340,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2004-07-22","marketCap":4.26347,"name":"NeuroMetrix Inc","phone":"17818909989.0","outstanding":1.09,"symbol":"NURO","website":"https://www.neurometrix.com/","industry":"Health Care"},"price":3.945,"year":2023,"month":11,"day":29,"weekday":"Wednesday","title":"Financial Performance Analysis of NeuroMetrix Inc","date":"2023-11-29","url":"/posts/2023/11/29/NURO","content":[{"section":"Revenue Analysis","text":"In the past three years, NeuroMetrix Inc's revenue has shown a downward trend. In 2018, the company reported revenue of $16.5 million, which decreased to $14.9 million in 2019, and further declined to $14.3 million in 2020. This indicates a consistent decrease in top-line growth over the analyzed period."},{"section":"Earnings Analysis","text":"NeuroMetrix Inc's earnings have also experienced volatility in recent years. In 2018, the company reported a net loss of $6.2 million, which improved to a net loss of $3.9 million in 2019. However, in 2020, the company's net loss increased to $7.1 million, indicating a significant decline in profitability."},{"section":"Cash Flow Analysis","text":"Despite the fluctuating revenue and earnings, NeuroMetrix Inc has maintained a relatively stable cash flow. In 2018, the company generated $2.1 million in operating cash flow, which increased slightly to $2.3 million in 2019. In 2020, the company's operating cash flow further improved to $2.6 million, indicating consistent cash generation and better overall financial health."},{"section":"Conclusion","text":"NeuroMetrix Inc has faced challenges in terms of declining revenue and increasing losses in recent years. However, the company has managed to maintain stable cash flow, which can be attributed to effective cost management or other sources of income. Investors should closely monitor future developments to assess the company's ability to turn the tides and regain profitability."}],"tags":["CrossOver100","Long","Health Care"],"news":[{"category":"company","date":1700549400,"headline":"NeuroMetrix trading halted, news pending","id":124069288,"image":"","symbol":"NURO","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3223494541"},{"category":"company","date":1700488800,"headline":"NeuroMetrix Announces One-for-Eight Reverse Stock Split","id":123998046,"image":"https://s.yimg.com/ny/api/res/1.2/8Yg77NP0_Ca7I04gKr4e6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xNTA-/https://media.zenfs.com/en/globenewswire.com/6781c6c0d824f329c9ea1721f4feaf2f","symbol":"NURO","publisher":"Yahoo","summary":"WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the “Effective Time”). The shares underlying the Company's outstanding options will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued lis","url":"https://finance.yahoo.com/news/neurometrix-announces-one-eight-reverse-140000089.html"}]}